Alnylam Pharmaceuticals | ALNY - Trade Creditors


Alnylam Pharmaceuticals reported $108.02M in Trade Creditors for its fiscal quarter ending in June of 2026.





Trade Creditors Change Date
Acadia Pharmaceuticals USD 44.57M 32.32M Jun/2026
Agios Pharmaceuticals USD 16.34M 2.6M Jun/2026
Alnylam Pharmaceuticals USD 108.02M 18.61M Jun/2026
Amgen USD 2.86B 16.65B Jun/2026
Arrowhead Research USD 27.78M 2.97M Jun/2026
BioCryst Pharmaceuticals USD 11.46M 501K Jun/2026
BioMarin Pharmaceutical USD 913.67M 120.52M Jun/2026
Incyte USD 1.39B 1.16B Jun/2026
Ionis Pharmaceuticals USD 47.7M 21.67M Jun/2026
Moderna USD 167M 6M Jun/2026
Neurocrine Biosciences USD 691.3M 145.8M Mar/2026
Novartis USD 4.32B 134M Mar/2026
PTC Therapeutics USD 40.45M 14.96M Jun/2026
Regeneron Pharmaceuticals USD 1.16B 132.2M Jun/2026
Sangamo BioSciences USD 10.74M 7.46M Jun/2025
Sanofi EUR 22.71B 219M Mar/2026
Sarepta Therapeutics USD 50.98M 19.39M Jun/2026
Takeda JPY 446.78B 44.56B Jun/2026
Tectonic Therapeutic USD 2.55M 1.46M Mar/2026
Ultragenyx Pharmaceutical USD 39M 3M Jun/2026
Vertex Pharmaceuticals USD 3.61B 135M Jun/2026
Xencor USD 12.65M 4.73M Jun/2026